Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Aditxt, Inc. (ADTX)
USD0.00
0.00 (-8.33%)
US NASDAQ Healthcare Biotechnology
Address
737 North Fifth Street 23219
Mountain View, VA, US
Mountain View, VA, US
CEO
Amro A. Albanna
Website
aditxt.com
IPO
2020-06-30
CIK 1726711 ISIN US0070258696
Description
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
0.00 (-8.33%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
405M
Beta
0.81
Float Shares
32.8K
Free Float %
97.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -28.54% | -65.27% | -97.78% | -99.88% | -99.99% | -99.94% | -100.00% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
0.00
Low
1,280.00
+38,787,778.8%
Consensus
1,280.00
+38,787,778.8%
Median
1,280.00
+38,787,778.8%
High
1,280.00
+38,787,778.8%
DCF (Unlevered)
5,101.10
+154,578,648.6%
DCF (Levered)
5,140.48
+155,771,880.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | — | — |
| Last Quarter | — | — |
| Last Year | — | — |
| All Time | 1 |
1,280.00
+38,787,778.8%
|
Quality scores
Altman Z-Score
-33.10
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
0 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-97.6% Q1'26: +1,094.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+62.3% ★ Q1'26: -9,635.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1,532,360.8% Q1'26: -37,742.3% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-1,264,450.4% Q1'26: -35,873.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%— Q1'26: +55.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+183.5% Q1'26: -71.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-74.93× Q1'26: -0.25× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2021 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
105.0K
est: 11.00M (-99.0%)
|
105.0K
est: 11.00M (-99.0%)
|
933.7K
est: 1.41M (-34.0%)
|
933.7K
est: 1.41M (-34.0%)
|
645.2K
est: 700.0K (-7.8%)
|
134.0K
est: 1.48M (-90.9%)
|
3.2K
est: 1.20M (-99.7%)
|
1.26M
1.26M – 1.26M
+5.0% YoY
|
1.32M
1.32M – 1.32M
+5.0% YoY
|
1.39M
1.39M – 1.39M
+5.0% YoY
|
| EBITDA |
-43.96M
est: -6.60M (-566.0%)
|
-43.96M
est: -11.00M (-299.6%)
|
-24.83M
est: -848.4K (-2,826.4%)
|
-24.83M
est: -1.41M (-1,655.9%)
|
-25.46M
est: -700.0K (-3,536.9%)
|
-27.04M
est: -1.48M (-1,733.2%)
|
-40.13M
est: -1.20M (-3,243.9%)
|
-1.26M
-1.26M – -1.26M
-5.0% YoY
|
-1.32M
-1.32M – -1.32M
-5.0% YoY
|
-1.39M
-1.39M – -1.39M
-5.0% YoY
|
| EBIT |
-44.43M
est: -6.60M (-573.2%)
|
-44.43M
est: -11.00M (-303.9%)
|
-25.36M
est: -848.4K (-2,889.6%)
|
-25.36M
est: -1.41M (-1,693.8%)
|
-26.00M
est: -700.0K (-3,614.4%)
|
-27.66M
est: -1.48M (-1,775.0%)
|
-40.40M
est: -1.20M (-3,266.6%)
|
-1.26M
-1.26M – -1.26M
-5.0% YoY
|
-1.32M
-1.32M – -1.32M
-5.0% YoY
|
-1.39M
-1.39M – -1.39M
-5.0% YoY
|
| Net Income |
-46.37M
est: -225.93B (+100.0%)
|
-46.37M
est: -5,740.73T (+100.0%)
|
-27.65M
est: -27.75B (+99.9%)
|
-27.65M
est: -705.10T (+100.0%)
|
-32.38M
est: -272.92T (+100.0%)
|
-34.45M
est: -102.94T (+100.0%)
|
-41.71M
est: -838.57T (+100.0%)
|
-852.79T
-852.79T – -852.79T
-1.7% YoY
|
-867.29T
-867.29T – -867.29T
-1.7% YoY
|
-3.61M
-3.61M – -3.61M
+100.0% YoY
|
| SGA |
22.42M
est: 848.83M (-97.4%)
|
22.42M
est: 12.12B (-99.8%)
|
17.84M
est: 109.11M (-83.7%)
|
17.84M
est: 1.56B (-98.9%)
|
18.88M
est: 771.49M (-97.6%)
|
16.48M
est: 1.63B (-99.0%)
|
16.38M
est: 1.32B (-98.8%)
|
1.39B
1.39B – 1.39B
+5.0% YoY
|
1.46B
1.46B – 1.46B
+5.0% YoY
|
1.53B
1.53B – 1.53B
+5.0% YoY
|
| EPS |
—
est: -1,921,000,000.00 (+100.0%)
|
—
est: -15,368,000,000.00 (+100.0%)
|
—
est: -235,944,000.00 (+100.0%)
|
—
est: -1,887,552,000.00 (+100.0%)
|
—
est: -730,612,800.00 (+100.0%)
|
-3,062.42
est: -2,755,663,200.00 (+100.0%)
|
-1,153.83
est: -22,448,037,600.00 (+100.0%)
|
-22,828,802,400.00
-22,828,802,400.00 – -22,828,802,400.00
-1.7% YoY
|
-23,216,889,600.00
-23,216,889,600.00 – -23,216,889,600.00
-1.7% YoY
|
-96.73
-96.73 – -96.73
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-65.96M
OE per share TTM
-2,630.19
Owner's Yield
-2,638,845.76%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
115,598.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
4
Beneficial owners (>5%)
9
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Altium Capital Management, LP | 511.1K | 2.40% | — | 511.1K | — | — | IA, PN | Delaware, United States of America | 2021-02-16 | ↗ |
| 2 | Altium Growth Fund, LP | 511.1K | 2.40% | — | 511.1K | — | — | PN | Delaware, United States of America | 2021-02-16 | ↗ |
| 3 | Altium Growth GP, LLC | 511.1K | 2.40% | — | 511.1K | — | — | OO | Delaware, United States of America | 2021-02-16 | ↗ |
| 4 | NAME OF REPORTING PERSONS | 415.7K | 9.00% | — | 415.7K | — | 415.7K | OO | Delaware, USA | 2023-01-04 | ↗ |
| 5 | Daniel B. Asher | 258.9K | 9.99% | — | 230.9K | — | 258.9K | HC, IN | United States of America | 2022-09-26 | ↗ |
| 6 | Intracoastal Capital LLC | 258.9K | 9.99% | — | 230.9K | — | 258.9K | OO | United States of America | 2022-09-26 | ↗ |
| 7 | Mitchell P. Kopin | 258.9K | 9.99% | — | 230.9K | — | 258.9K | HC, IN | United States of America | 2022-09-26 | ↗ |
| 8 | CVI Investments, Inc. | 242.3K | 9.90% | — | — | — | 242.3K | CO | Cayman Islands | 2022-09-27 | ↗ |
| 9 | Heights Capital Management, Inc. | 242.3K | 9.90% | — | — | — | 242.3K | CO | Cayman Islands | 2022-09-27 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
1
Sells
1
Shares acquired
72.9K
Shares disposed
12.0K
Cash buys
1.00
Cash sales
1.00
Net activity
+60,930
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-24 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Class A Shares | 29,404 | 0.28 | 8.2K | 88,377 | D | ↗ |
| 2026-04-23 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Class A Shares | 3,811 | 0.29 | 1.1K | 117,781 | D | ↗ |
| 2026-04-22 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Class A Shares | 11,982 | 0.30 | 3.6K | 121,592 | D | ↗ |
| 2026-04-21 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Class A Shares | 72,912 | 0.33 | 24.1K | 133,574 | D | ↗ |
| 2025-12-17 | Brady Brian Michael | Director | S-Sale | D | Common Stock | 1 | 1.75 | 1.75 | 3 | D | ↗ |
| 2025-11-25 | Pankovcin Corinne | Officer | S-Sale | D | Common Stock | 1 | 3.20 | 3.20 | 0 | D | ↗ |
| 2025-09-30 | Porcelli Christopher Jon | Officer | — | — | Common Stock | 0 | 0.00 | — | 0 | D | ↗ |
| 2025-06-05 | PELLETIER SAUNDRA L | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-23 | Hermina Sylvia | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-10-16 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Class A Shares | 25,534 | 1.17 | 29.9K | 0 | D | ↗ |
| 2024-10-15 | HRT FINANCIAL LP | 10% Owner | — | — | Class A Shares | 0 | 0.00 | — | 25,434 | D | ↗ |
| 2023-11-08 | Shabahang Shahrokh | Director / Officer | A-Award | A | Options (right to buy) | 7,053 | 5.01 | 35.3K | 7,053 | — | ↗ |
| 2023-11-08 | Runge Jeffrey W. | Director | A-Award | A | Options (right to buy) | 470 | 5.01 | 2.4K | 470 | — | ↗ |
| 2023-11-08 | Pankovcin Corinne | Officer | A-Award | A | Options (right to buy) | 4,702 | 5.01 | 23.6K | 4,702 | — | ↗ |
| 2023-11-08 | Nelson Charles Athle | Director | A-Award | A | Options (right to buy) | 470 | 5.01 | 2.4K | 470 | — | ↗ |
| 2023-11-08 | Farley Thomas J | Officer | A-Award | A | Options (right to buy) | 4,702 | 5.01 | 23.6K | 4,702 | — | ↗ |
| 2023-11-08 | Brady Brian Michael | Director | A-Award | A | Options (right to buy) | 470 | 5.01 | 2.4K | 470 | — | ↗ |
| 2023-11-08 | Albanna Rowena | Officer | A-Award | A | Options (right to buy) | 4,702 | 5.01 | 23.6K | 4,702 | — | ↗ |
| 2023-11-08 | Albanna Amro A. | Director / Officer | A-Award | A | Options (right to buy) | 9,404 | 5.01 | 47.1K | 9,404 | — | ↗ |
| 2023-11-03 | Nelson Charles Athle | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-09-07 | BNP PARIBAS SECURITIES CORP | — | S-Sale | D | Aditxt Inc | 20,800 | 33.23 | 691.1K | 22,342 | — | ↗ |
| 2023-08-31 | BNP PARIBAS SECURITIES CORP | 10% Owner | — | D | Aditxt Inc | 0 | 0.00 | — | 32,942 | — | ↗ |
| 2022-07-19 | Albanna Amro A. | Officer | P-Purchase | A | Series B Preferred Stock | 1 | 20,000.00 | 20.0K | 1 | — | ↗ |
| 2022-01-28 | Shatzkes Matthew | Officer | — | D | Restricted Stock Unit | 480,000 | 0.00 | — | 0 | — | ↗ |
| 2021-11-10 | Shabahang Shahrokh | Officer | A-Award | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2021-11-10 | Farley Thomas J | Officer | A-Award | A | Restricted Stock Unit | 95,000 | 0.00 | — | 95,000 | — | ↗ |
| 2021-11-10 | Albanna Rowena | Officer | A-Award | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2021-09-29 | Runge Jeffrey W. | Director | A-Award | A | Restricted Stock Units | 11,500 | 0.00 | — | 11,500 | — | ↗ |
| 2021-09-29 | Kiaie Namvar | Director | A-Award | A | Restricted Stock Units | 11,500 | 0.00 | — | 11,500 | — | ↗ |
| 2021-09-29 | Chung Lauren | Director | A-Award | A | Restricted Stock Units | 11,500 | 0.00 | — | 14,000 | — | ↗ |
| 2021-09-29 | Brady Brian Michael | Director | A-Award | A | Restricted Stock Units | 11,500 | 0.00 | — | 11,500 | — | ↗ |
| 2021-09-29 | ANTHONY LAURA E | Director | A-Award | A | Restricted Stock Units | 11,500 | 0.00 | — | 11,500 | — | ↗ |
| 2021-07-22 | Shabahang Shahrokh | Officer | A-Award | A | Restricted Stock Unit | 55,000 | 0.00 | — | 55,000 | — | ↗ |
| 2021-07-22 | Farley Thomas J | Officer | A-Award | A | Restricted Stock Unit | 60,000 | 0.00 | — | 60,000 | — | ↗ |
| 2021-06-16 | Chung Lauren | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-06-04 | Pankovcin Corinne | Officer | A-Award | A | Common Stock | 55,000 | 0.00 | — | 169,220 | — | ↗ |
| 2021-06-04 | Albanna Rowena | Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 826,620 | — | ↗ |
| 2021-06-04 | Albanna Amro A. | Director / Officer | A-Award | A | Common Stock | 75,000 | 0.00 | — | 826,620 | — | ↗ |
| 2021-06-01 | Shabahang Shahrokh | Director / Officer | P-Purchase | A | Common Stock | 490 | 2.93 | 1.4K | 1,016,098 | — | ↗ |
| 2021-06-01 | Runge Jeffrey W. | Director | P-Purchase | A | Common Stock | 1,600 | 2.93 | 4.7K | 5,500 | — | ↗ |
| 2021-06-01 | Albanna Rowena | Officer | P-Purchase | A | Common Stock | 1,000 | 2.95 | 3.0K | 749,720 | — | ↗ |
| 2021-06-01 | Albanna Amro A. | Director / Officer | P-Purchase | A | Common Stock | 800 | 2.90 | 2.3K | 751,520 | — | ↗ |
| 2021-05-27 | Shabahang Shahrokh | Director / Officer | P-Purchase | A | Common Stock | 185 | 2.70 | 499.50 | 1,015,608 | — | ↗ |
| 2021-05-26 | Farley Thomas J | Officer | P-Purchase | A | Common Stock | 2,500 | 2.68 | 6.7K | 2,500 | — | ↗ |
| 2021-05-25 | Shabahang Shahrokh | Director / Officer | P-Purchase | A | Common Stock | 138 | 2.38 | 328.44 | 1,015,423 | — | ↗ |
| 2021-05-25 | Pankovcin Corinne | Officer | P-Purchase | A | Common Stock | 4,220 | 2.56 | 10.8K | 114,220 | — | ↗ |
| 2021-03-19 | Farley Thomas J | Officer | — | D | Stock Option (Right to Buy) | 60,000 | 1.92 | 115.2K | 0 | — | ↗ |
| 2021-03-17 | Shabahang Shahrokh | Director / Officer | O-OutOfTheMoney | A | Common Stock | 18,750 | 4.00 | 75.0K | 1,015,006 | — | ↗ |
| 2021-02-24 | Pankovcin Corinne | Officer | A-Award | A | Common Stock | 110,000 | 0.00 | — | 110,000 | — | ↗ |
| 2021-02-24 | Albanna Rowena | Officer | A-Award | A | Common Stock | 225,000 | 0.00 | — | 772,220 | — | ↗ |
| 2021-02-24 | Albanna Amro A. | Director / Officer | A-Award | A | Common Stock | 225,000 | 0.00 | — | 772,220 | — | ↗ |
| 2020-11-02 | Shabahang Shahrokh | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 110,000 | 1.92 | 211.2K | 110,000 | — | ↗ |
| 2020-11-02 | Pankovcin Corinne | Officer | A-Award | A | Stock Option (Right to Buy) | 165,000 | 1.92 | 316.8K | 165,000 | — | ↗ |
| 2020-11-02 | Albanna Rowena | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 1.92 | 192.0K | 100,000 | — | ↗ |
| 2020-11-02 | Albanna Amro A. | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 1.92 | 192.0K | 100,000 | — | ↗ |
| 2020-10-13 | Runge Jeffrey W. | Director | A-Award | A | Stock Option (Right to Buy) | 10,000 | 1.94 | 19.4K | 10,000 | — | ↗ |
| 2020-10-13 | Kiaie Namvar | Director | D-Return | D | Stock Option (Right to Buy) | 10,000 | 1.94 | 19.4K | 10,000 | — | ↗ |
| 2020-10-13 | Brady Brian Michael | Director | D-Return | D | Stock Option (Right to Buy) | 10,000 | 1.94 | 19.4K | 10,000 | — | ↗ |
| 2020-10-13 | ANTHONY LAURA E | Director | D-Return | D | Stock Option (Right to Buy) | 10,000 | 1.94 | 19.4K | 10,000 | — | ↗ |
| 2020-07-24 | Shabahang Shahrokh | Director / Officer | X-InTheMoney | D | Series B Warrant | 47,222 | 0.00 | — | 0 | — | ↗ |
| 2020-07-24 | Albanna Rowena | Officer | X-InTheMoney | A | Common Stock | 35,555 | 11.25 | 400.0K | 71,110 | — | ↗ |
| 2020-07-24 | Albanna Amro A. | Director / Officer | X-InTheMoney | A | Common Stock | 38,055 | 11.25 | 428.1K | 476,110 | — | ↗ |
| 2020-07-22 | Kiaie Namvar | Director | X-InTheMoney | D | Series B Warrant | 1,111 | 0.00 | — | 0 | — | ↗ |
| 2020-07-10 | Runge Jeffrey W. | Director | — | I | Common Stock | 0 | 0.00 | — | 2,500 | — | ↗ |
| 2020-07-10 | McLeod Rosland Fisher | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-10 | Albanna Rowena | Officer | — | I | Common Stock | 0 | 0.00 | — | 438,055 | — | ↗ |
| 2020-07-02 | Shabahang Shahrokh | Director / Officer | — | I | Series B Warrant | 47,222 | 11.25 | 531.2K | 0 | — | ↗ |
| 2020-07-02 | Pankovcin Corinne | Officer | — | D | Stock Option (Right to Buy) | 165,000 | 9.00 | 1.49M | 0 | — | ↗ |
| 2020-07-02 | Kiaie Namvar | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-07-02 | Albanna Rowena | Officer | — | D | Series A Warrant | 35,555 | 9.00 | 320.0K | 0 | — | ↗ |
| 2020-07-02 | Albanna Amro A. | Director / Officer | — | D | Series B Warrant | 38,055 | 11.25 | 428.1K | 0 | — | ↗ |
| 2020-07-02 | ANTHONY LAURA E | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-06-29 | Shabahang Shahrokh | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 949,034 | — | ↗ |
| 2020-06-29 | Brady Brian Michael | Director | — | D | Common Stock | 0 | 0.00 | — | 12,500 | — | ↗ |
| 2020-06-29 | Albanna Amro A. | Director / Officer | — | I | Common Stock | 0 | 0.00 | — | 438,055 | — | ↗ |
| 2020-03-20 | Pankovcin Corinne | Officer | — | D | Stock Option (Right to Buy) | 7,500 | 11.00 | 82.5K | 0 | — | ↗ |
| 2018-03-08 | Shabahang Shahrokh | Director / Officer | — | I | Warrant | 172,931 | 4.00 | 691.7K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-15.5K
Shares Outstanding
33.5K
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Amro Albanna Chief Executive Officer and Director | 500.0K | — | — | — | — | — | 500.0K | 0.00% | ↗ |
| 2 | 2025 | Thomas J. Farley Chief Financial Officer | 395.0K | — | — | — | — | — | 395.0K | 0.00% | ↗ |
| 3 | 2025 | Corinne Pankovcin Chief Mergers & Acquisitions Officer | 385.0K | — | — | — | — | — | 385.0K | 0.00% | ↗ |
| 4 | 2025 | Shahrokh Shabahang, D.D.S., MS, Ph.D. Chief Innovation Officer | 325.0K | — | — | — | — | — | 325.0K | 0.00% | ↗ |
| 5 | 2024 | Amro Albanna Chief Executive Officer and Director | 500.0K | — | — | — | — | — | 500.0K | 0.00% | ↗ |
| 6 | 2024 | Thomas J. Farley Chief Financial Officer | 395.0K | — | — | — | — | — | 395.0K | 0.00% | ↗ |
| 7 | 2024 | Corinne Pankovcin Chief Mergers & Acquisitions Officer | 385.0K | — | — | — | — | — | 385.0K | 0.00% | ↗ |
| 8 | 2024 | Shahrokh Shabahang, D.D.S., MS, Ph.D. Chief Innovation Officer | 325.0K | — | — | — | — | — | 325.0K | 0.00% | ↗ |
| 9 | 2023 | Matthew Shatzkes Chief Legal Officer & General Counsel | 198.7K | 890.9K | — | — | — | 34.1K | 1.12M | 0.00% | ↗ |
| 10 | 2023 | Matthew Shatzkes Former Chief Legal Officer & General Counsel | 198.7K | 890.9K | — | — | — | 34.1K | 1.12M | 0.00% | ↗ |
| 11 | 2023 | Amro Albanna President, and Director, Former President | 432.1K | — | — | 47.1K | — | 40.0K | 519.2K | 9.07% | ↗ |
| 12 | 2023 | Amro Albanna Chief Executive Officer and Director | 432.1K | — | — | 47.1K | — | 40.0K | 519.2K | 9.07% | ↗ |
| 13 | 2023 | Corinne Pankovcin Chief Commercialization Officer, Former President, Former Chief Financial Officer | 346.8K | — | — | 23.6K | — | 20.0K | 390.3K | 6.04% | ↗ |
| 14 | 2023 | Corinne Pankovcin Chief Mergers & Acquisitions Officer | 346.8K | — | — | 23.6K | — | 20.0K | 390.3K | 6.04% | ↗ |
| 15 | 2023 | Thomas J. Farley Chief Financial Officer | 337.9K | — | — | 23.6K | — | 20.0K | 381.5K | 6.18% | ↗ |
| 16 | 2023 | Shahrokh Shabahang, D.D.S., MS, Ph.D. Chief Innovation Officer | 293.5K | — | — | 35.3K | — | 30.0K | 358.8K | 9.85% | ↗ |
| 17 | 2022 | Matthew Shatzkes Chief Legal Officer & General Counsel | 369.0K | 246.7K | 218.1K | — | — | — | 833.7K | 26.16% | ↗ |
| 18 | 2022 | Amro Albanna President, and Director, Former President | 500.0K | — | — | — | — | — | 500.0K | 0.00% | ↗ |
| 19 | 2022 | Corinne Pankovcin Chief Commercialization Officer, Former President , Former Chief Financial Officer | 385.0K | — | — | — | — | — | 385.0K | 0.00% | ↗ |
| 20 | 2022 | Corinne Pankovcin Chief Commercialization Officer, Former President, Former Chief Financial Officer | 385.0K | — | — | — | — | — | 385.0K | 0.00% | ↗ |
| 21 | 2022 | Thomas J. Farley Chief Financial Officer | 360.8K | — | — | — | — | — | 360.8K | 0.00% | ↗ |
| 22 | 2022 | Shahrokh Shabahang, D.D.S., MS, Ph.D. Chief Innovation Officer | 325.0K | — | — | — | — | — | 325.0K | 0.00% | ↗ |
| 23 | 2021 | Amro Albanna President, and Director, Former President | 280.0K | 470.0K | 938.3K | — | — | — | 1.69M | 55.58% | ↗ |
| 24 | 2021 | Corinne Pankovcin President, Former Chief Financial Officer | 250.0K | 333.3K | 505.5K | — | — | — | 1.09M | 46.43% | ↗ |
| 25 | 2021 | Corinne Pankovcin Chief Commercialization Officer, Former President , Former Chief Financial Officer | 250.0K | 333.3K | 505.5K | — | — | — | 1.09M | 46.43% | ↗ |
| 26 | 2021 | Thomas J. Farley Chief Financial Officer | 225.0K | 297.0K | 304.9K | — | — | — | 826.9K | 36.87% | ↗ |
| 27 | 2021 | Shahrokh Shabahang, D.D.S., MS, Ph.D. Chief Innovation Officer | 210.0K | 245.0K | 210.1K | — | — | — | 665.1K | 31.59% | ↗ |
| 28 | 2020 | Corinne Pankovcin Chief Financial Officer | 225.0K | — | — | 225.4K | — | — | 450.4K | 50.04% | ↗ |
| 29 | 2020 | Corinne Pankovcin President, Former Chief Financial Officer | 225.0K | — | — | 225.4K | — | — | 450.4K | 50.04% | ↗ |
| 30 | 2020 | Amro Albanna Chief Executive Officer, President, and Director | 252.0K | — | — | — | — | — | 252.0K | 0.00% | ↗ |
| 31 | 2020 | Amro Albanna President, and Director, Former President | 252.0K | — | — | — | — | — | 252.0K | 0.00% | ↗ |
| 32 | 2020 | Shahrokh Shabahang, D.D.S., MS, Ph.D. Chief Innovation Officer | 210.0K | — | — | 16.3K | — | — | 226.3K | 7.20% | ↗ |
| 33 | 2020 | Shahrokh Shabahang, MS, Ph.D. Chief Innovation Officer | 210.0K | — | — | 16.3K | — | — | 226.3K | 7.20% | ↗ |
| 34 | 2019 | Amro Albanna Chief Executive Officer, President, and Director | 252.0K | — | — | 1.43M | — | — | 1.68M | 84.98% | ↗ |
| 35 | 2019 | Shahrokh Shabahang, MS, Ph.D. Chief Innovation Officer | 204.0K | — | — | — | — | — | 204.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Amro A. Albanna | Co-Founder, Chairman & Chief Executive Officer | 500.0K | male |
| Thomas J. Farley | Chief Financial Officer | 395.0K | male |
| Corinne D. Pankovcin | Chief Mergers & Acquisitions Officer | 385.0K | female |
| Shahrokh Shabahang | Co-Founder, Chief Innovation Officer, Secretary & Director | 325.0K | — |
| Ge Chen | Senior Vice President of Preclinical Research & Discovery | — | male |
| Rowena Albanna | Chief Operating Officer | — | female |
| Christopher J. Porcelli | General Counsel & Chief People Officer | — | male |
| Jennifer Lee | Director of Human Resources | — | female |
| Dolly Tyan | Senior Vice President of Clinical Development Transplantation | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for ADTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
